thymalfasin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-26 and is reviewed periodically as new material appears.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Biko opposed any collaboration with the apartheid government, such as the agreements that the Coloured and Indian communities made with the regime. In his view, the Bantustan system was "the greatest single fraud ever invented by white politicians", stating that it was designed to divide the Bantu-speaking African population along tribal lines. He openly criticised the Zulu leader Mangosuthu Buthelezi, stating that the latter's co-operation with the South African government "[diluted] the cause" of black liberation. He believed that those fighting apartheid in South Africa should link with anti-colonial struggles elsewhere in the world and with activists in the global African diaspora combating racial prejudice and discrimination. He also hoped that foreign countries would boycott South Africa's economy. Biko believed that while apartheid and white-minority rule continued, "sporadic outbursts" of violence against the white minority were inevitable. He wanted to avoid violence, stating that "if at all possible, we want the revolution to be peaceful and reconciliatory". He noted that views on violence differed widely within the BCM – which contained both pacifists and believers in violent revolution – although the group had agreed to operate peacefully, and unlike the PAC and ANC, had no armed wing. A staunch anti-imperialist, Biko saw the South African situation as a "microcosm" of the broader "black–white power struggle" which manifests as "the global confrontation between the Third World and the rich white nations of the world".
== Routes of administration == Since they are not absorbed from the gut, they are administered intravenously and intramuscularly. Some are used in topical preparations for wounds. Oral administration can be used for gut decontamination (e.g., in hepatic encephalopathy). Tobramycin may be administered in a nebulized form.
=== Weaning === Weaning is the process of replacing breast milk with other foods; the infant is fully weaned after the replacement is complete. Psychological factors affect the weaning process for both mother and infant, as issues of closeness and separation are very prominent. Unless a medical emergency necessitates abruptly stopping breastfeeding, it is best to gradually increase the period between feedings or eliminate feedings to allow the breasts to adjust to the decreased demands without becoming engorged. Studies show that a large number of women discontinue breastfeeding early due to lack of working place support for breastfeeding mothers. La Leche League advises parents to shift their children's focus at bedtime away from breastfeeding, as it is often the most difficult feeding for them to let go. If weaning starts at 12 months or later, it is not necessary to switch to infant formula or "toddler formula" as is sold commercially. At 12 months, it is recommended that the baby be switched to whole cow's milk. Reduced-fat or skim milk generally is not appropriate before age 2 because it lacks sufficient fat or calories to promote early brain development. If the mother was experiencing lactational amenorrhea, periods will begin to return with weaning, along with restored fertility.
GABAergic pro-drugs include chloral hydrate, which is metabolised to trichloroethanol, which then acts via the GABAA receptor. The plant kava contains GABAergic compounds, including kavain, dihydrokavain, methysticin, dihydromethysticin and yangonin.
A 2017 study in The BMJ by Tim Dyson and Valeria Cetorelli concluded that "Saddam Hussein's government successfully manipulated the 1999 survey in order to convey a very false impression." In the case of Cuba, a declassified 1960 U.S. State Department memorandum by diplomat Lester D. Mallory argued that "every possible means should be undertaken promptly to weaken the economic life of Cuba" by denying money and supplies in order "to bring about hunger, desperation and overthrow of government." A 2025 study funded by the Center for Economic and Policy Research, authored by Mark Weisbrot, Francisco Rodríguez, and Silvio Rendón and published in The Lancet, estimated that unilateral sanctions by all parties—including those of the United States, United Nations, and European Union—were associated with as many as 564,258 deaths annually between 1971 and 2021. The study found "significant causal association between sanctions and increased mortality" with "the strongest effects for unilateral, economic, and US sanctions." Writing in Al Jazeera about this study, Jason Hickel, Dylan Sullivan, and Omer Tayyab estimated that unilateral sanctions imposed by the United States and European Union since 1970 were associated with approximately 38 million deaths worldwide, with more than half of the victims being children and the elderly, and that sanctions kill several times more people each year than die as direct casualties of war.
Sources: en.wikipedia.org
== CMS/Regulatory == In November 2006, the Centers for Medicare & Medicaid Services (CMS) approved ACHC to accredit suppliers of durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) as meeting new quality standards under Medicare Part B. In January 2009, the Centers for Medicare & Medicaid Services (CMS) announced the approval of the ACHC for continued Deeming Authority for Home Health Agencies through 2015. Initial approval of Deeming Authority of ACHC for Home Health Agencies was granted in February 2006. On November 27, 2009, ACHC was recognized by the Centers for Medicare & Medicaid Services (CMS) as a national accreditation organization for Hospices that request participation in the Medicare program.
=== Discontinued === Amibegron (SR-58611; SR-58611A) – β3-adrenergic receptor agonist [26] BTG-1640 (ABIO-08/01; ABIO-0801) – undefined mechanism of action [27] Darigabat (CVL-865; PF-06372865; PF-6372865) – GABAA receptor positive allosteric modulator [28] Imagabalin (PD-0332334; PD-332334; PF-00195889) – α2δ subunit-containing voltage-gated calcium channel ligand [29] Naluzotan (PRX-00023) – serotonin 5-HT1A receptor agonist and sigma σ1 receptor agonist [30] Ocinaplon (CL-273547) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/pyrazolopyrimidine [31] Pagoclone (IP-456; Panex; RP-62955) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [32] PF-572778 – undefined mechanism of action [33] Rufinamide (Banzel; CGP-33101; E-2080; Inovelon; RUF-331; SYN-111) – sodium channel blocker and other actions [34] Talaglumetad (LY-544344) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (eglumetad prodrug) [35] Tedatioxetine (Lu-AA24530) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), serotonin 5-HT2A, 5-HT2C, and 5-HT3 receptor antagonist, and α1A-adrenergic receptor antagonist [36]
== Ionization == The gastrointestinal tract is lined with epithelial cells. Drugs must pass through or permeate these cells to be absorbed into the bloodstream. Cell membranes may act as barriers to some drugs. They are essentially lipid bilayers which form semipermeable membranes. Pure lipid bilayers are generally permeable only to small, uncharged solutes. Hence, whether or not a molecule is ionized will affect its absorption, since ionic molecules are charged. Solubility favors charged species, and permeability favors neutral species. Some molecules have special exchange proteins and channels to facilitate movement from the lumen into the circulation. Ions cannot passively diffuse through the gastrointestinal tract because the epithelial cell membrane is made up of a phospholipid bilayer, comprising two layers of phospholipids in which the charged hydrophilic heads face outwards and the uncharged hydrophobic fatty acid chains are in the middle of the layer. The fatty acid chains repel ionized, charged molecules. This means that the ionized molecules cannot pass through the intestinal membrane and be absorbed. The Henderson-Hasselbalch equation offers a way to determine the proportion of a substance that is ionized at a given pH. In the stomach, drugs that are weak acids (such as aspirin) will be present mainly in their non-ionic form, and weak bases will be in their ionic form. Since non-ionic species diffuse more readily through cell membranes, weak acids will have a higher absorption in the highly acidic stomach.
=== April === 1 April An entirely new class of antibiotics with potent activity against multi-drug resistant bacteria is discovered. These compounds target a protein called LpxH, and are shown to cure bloodstream infections in mice. An analysis of the European Union's Common Agricultural Policy suggests 82% of the EU's agricultural subsidies are used for animal-based foods which "are associated with 84% of embodied greenhouse gas emissions of EU food production".
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.